111 related articles for article (PubMed ID: 336181)
1. A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma.
Laucius JF; Bodurtha AJ; Mastrangelo JM; Bellet RE
Cancer; 1977 Nov; 40(5):2091-3. PubMed ID: 336181
[TBL] [Abstract][Full Text] [Related]
2. BCG immunotherapy in previously treated malignant melanoma patients.
Mujagić H; Kolarić K; Malenica B; Nola P
Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Berd D; Maguire HC; McCue P; Mastrangelo MJ
J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
[TBL] [Abstract][Full Text] [Related]
4. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
5. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
Coates AS; Peters M
Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
[TBL] [Abstract][Full Text] [Related]
6. [Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].
Balzarini GP; Cascinelli N; Fontana V; Veronesi U
Tumori; 1974; 60(4):345-52. PubMed ID: 4439501
[No Abstract] [Full Text] [Related]
7. Intralesional BCG in the treatment of metastatic malignant melanoma.
Mastrangelo MJ; Sulit HL; Prehn LM; Bornstein RS; Yarbro JW; Prehn RT
Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
10. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
[TBL] [Abstract][Full Text] [Related]
12. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of cyclophosphamide, vincristine and D.T.I.C. +/- B.C.G. in the treatment of malignant melanoma.
Byrne MJ; Reynolds PM
Aust N Z J Med; 1982 Aug; 12(4):263-6. PubMed ID: 6958237
[TBL] [Abstract][Full Text] [Related]
14. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
15. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
[TBL] [Abstract][Full Text] [Related]
16. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
Hedley DW; McElwain TJ; Currie GA
Br J Cancer; 1978 Apr; 37(4):491-6. PubMed ID: 646922
[TBL] [Abstract][Full Text] [Related]
17. Management of recurrent melanoma of the extremity.
Shingleton WW; Seigler HF; Stocks LH; Downs RW
Cancer; 1975 Mar; 35(3):574-9. PubMed ID: 234293
[TBL] [Abstract][Full Text] [Related]
18. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Deutschmann KE; Peter HH; Schultheis W; Deicher H
Tumori; 1977; 63(3):303-7. PubMed ID: 898298
[TBL] [Abstract][Full Text] [Related]
19. Inconsistent response of B16 melanoma to BCG immunotherapy.
Kreider JW; Bartlett GL; Purnell DM
J Natl Cancer Inst; 1976 Apr; 56(4):803-10. PubMed ID: 1255799
[TBL] [Abstract][Full Text] [Related]
20. Risks of BCG intralesional therapy: an experience with melanoma.
Robinson JC
J Surg Oncol; 1977; 9(6):587-93. PubMed ID: 145518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
